Smooth muscle cell (SMC) apoptosis is transiently increased at the onset of the regression of aortic hypertrophy in spontaneously hypertensive rats (SHR) treated with the angiotensin II AT 1 antagonist losartan.We postulated that losartan induction of SMC apoptosis contributes to suppression of neointimal hyperplasia after vascular injury. Losartan or placebo treatment was initiated two days before balloon injury in the SHR aorta. Compared with time-matched placebo, losartan decreased neointimal cross-sectional area at Days 5 and 10 after injury by 50% and 64% respectively, without affecting medial mass. At Day 10, losartan significantly decreased SMC number (by 56%) in the neointima, but not in the media. DNA synthesis was significantly inhibited at Day 5 but not at Day 10. Losartan significantly increased aortic DNA fragmentation by 2.6-and 4.1fold, at Days 5 and 10, respectively. In situ labeling of SMC with terminal deoxynucleotidyltransferase revealed significant 61% and 68% increases in apoptotic SMC at Days 5 and 10 with losartan treatment, predominantly in the neointima. Thus, losartan suppressed neointima formation in part by the induction of SMC apoptosis, which may be dissociated from the inhibition of DNA synthesis. Therefore, losartan-induced SMC apoptosis may be a potential therapeutic approach to control occlusive vascular disorders.
Introduction
Several animal models of vascular lesion formation have implicated angiotensin (Ang) II as a stimulant of neointimal hyperplasia. Losartan is a selective angiotensin II type 1 (AT 1 ) receptor antagonist which inhibits vascular smooth muscle cell (SMC) contraction, proliferation and migration.The potential of losartan in the treatment of vascular occlusive disorders is currently the subject of growing interest. Neointima formation after vascular injury is a complex condition that involves increased SMC proliferation, migration and apoptosis. Studies of cultured rat SMC and human aortic and coronary SMC show that losartan and other AT 1 antagonists inhibit DNA synthesis, SMC proliferation and migration and protein synthesis. [1] [2] [3] [4] [5] In vivo, AT 1 antagonists inhibit neointima formation after balloon injury in animal models by decreasing medial SMC proliferation and migration. 1, [6] [7] [8] [9] [10] [11] [12] [13] In the neointima, however, SMC DNA synthesis is not affected by blockade of the angiotensin II pathway. 14 The regulation of SMC apoptosis in the injured vessel wall remains poorly defined. We recently demonstrated that losartan reduces aortic medial hypertrophy by inducing SMC apoptosis in spontaneously hypertensive rats (SHR). 15 Whether AT 1 antag-onists suppress neointimal hyperplasia by up-regulating SMC apoptosis in the injured vessel wall remains unclear. Thus, the aim of this study is to determine whether SMC apoptosis induced by losartan can contribute to the prevention of lesion development after in vivo balloon angioplasty in the SHR aorta.
Methods

Vascular injury and tissue isolation
Vascular injury to the thoracic aorta of 11 week-old male SHR (Charles River Laboratories, St-Constant, Canada) was performed in accordance with institutional guidelines. Briefly, animals were anesthetized with a single intramuscular injection of ketamine (50 mg/kg; MTC Pharmaceuticals, Cambridge, Canada), xylazine (5 mg/kg; Bayer, Etobicoke, Canada) and acepromazine (2.5 mg/kg;Ayerst Laboratories, Montreal, Canada).A balloon catheter was inserted through the left common carotid artery and dilated to denude the thoracic aorta as previously described. 16 The neointima was allowed to develop for a period of 5 days (n=4 rats/group) and 10 days (n=5 rats/group) and animals received food and water ab libitum during this period. Losartan (30 mg/kg/day in the drinking water) or placebo (vehicle) was administered starting 2 days before surgery as previously described. 6, 7, 15 One hour before sacrifice, animals received a single intra-venous injection of 3 H-thymidine (0.5mCi/kg, ICN Biochemicals, St-Laurent, Canada) to evaluate DNA synthesis.The thoracic aorta was isolated from the diaphragm to above the 1st intercostal artery, flushed with ice-cold saline solution and cleaned free of adherent adipose and connective tissue.Tissue sections between the 3rd and 4th intercostal arteries were taken for histological studies and the rest of the aorta was snapped frozen in liquid nitrogen and stored at -80°C until further processing.A section of the small intestine was used as a positive control for histological studies because of the high apoptosis rate of the intestinal epithelium.
Histological studies
Tissue were fixed in a 4% paraformaldehyde solution, processed according to routine histological procedures, paraffin-embedded and cut into 5 µm sections.To measure vascular mass, slides were stained with hematoxyline (Sigma, MO, USA) and the cross-sectional area (mm 2 ) of the media and neointima was evaluated separately. Pictures of arterial sections were taken at a 40X magnification with a Zeiss Axioskop microscope connected to a Polaroid Digital Camera and a Power Macintosh Performa 6360 computer. CSA measurements were made using the public domain NIH Image program 1.61 (developed at the National Institute of Health and available on the Internet at http://rsb.info.nih. gov/nih-image/). SMC nuclei showing evidence of internucleosomal DNA fragmentation, a hallmark of apoptosis, were detected using terminal deoxynucleotidyl-transferase (TdT) and digoxigenin-labeled dNTP, using a kit as per the manufacturer's recommendations (Apoptag Kit, Intergen, NY, USA).TdT-positive cells were detected by an immunoperoxidase reaction using an anti-digoxigenin antibody (Apoptag Kit, Intergen, NY, USA) and 3,3'-diaminobenzidine tetrahydrochloride (DAB) (Sigma, MO, USA) as a substrate, which precipitates as a dark crystal in the presence of peroxidase activity. The slides were counter-stained with hematoxyline to evaluate the total number of SMC nuclei per cross-section. Labeled nuclei located in the lumen or on the first layer of the neointimal surface were not counted. The percentage of labeled nuclei and total SMC nuclei was evaluated separately for the media and neointima. In situ labeling of endothelium was carried out as previously described 17 by immunodetection of the endothelial cell marker von Willebrand Factor by using a primary rabbit polyclonal antibody raised against human factor VIII-related antigen (Dako Laboratory, CA, USA) and a secondary anti-rabbit IgG (Santa Cruz, CA, USA) conjugated to horseradish peroxidase.
DNA analysis
The whole aorta was pulverized in liquid nitrogen with the use of a mortar and pestle to obtain a fine tissue powder which was stored at -80°C. An aliquot of the pulverized aorta was weighed, digested with proteinase K and RNase A in the presence of EDTA and total tissue DNA was extracted with phenol / chloroform by a procedure as previously described. 18 DNA concentration was evaluated by spectrophotometry and the DNA content per aorta was calculated. DNA fragmentation was measured as previously described. 15 Briefly, 1 µg of extracted DNA and molecular weight marker were radiolabeled using a terminal deoxynucleotidyl transferase assay and 32 P-dCTP. Increasing quantities of labeled DNA (0.05, 0.1, 0.2 and 0.4 µg) or marker (0.05 µg) were loaded on a 1.5% agarose gel.After electrophoresis, DNA was transferred onto a nylon membrane (Hybond N, Amersham Pharmacia Biotech, Quebec, Canada) and the radioactivity associated with the 150-1500 bp DNA fragments was quantified using a PhosphoImager. Radioactivity (cpm/pixel) was normalized with molecular weight marker value of radioactivity and was plotted as a function of the quantity of DNA loaded. A linear regression was calculated and provided a slope value, which was defined as DNA fragmentation index. Finally, 3 H-thymidine incorporation in vivo was used to evaluate DNA synthesis; an aliquot (10 µg) of extracted DNA was mixed in 5 mL of scintillation liquid and radioactivity was measured with a beta-counter (1600 TR Liquid Scintillation Analyzer, Canberra Packard, Canada).
Statistical analysis
The data are expressed as mean±SEM. Data from paired groups at Day 5 or Day 10, respectively were analyzed using Student's t-test for unpaired samples. A value of P<0.05 was considered statistically significant.
Results
Vascular mass and hyperplasia
At the time of sacrifice, there was no difference in body weight between the placebo and losartan groups (at Day 5 : 233±5g and 239±4g, respectively; and at Day 10 : 274±4g and 265±6g, respectively). Treatment with losartan significantly reduced the cross-sectional area of the neointima, by 50% and 64% at Days 5 and 10 respectively as compared with time-matched placebo ( Figure  1A) . In contrast, cross-sectional area of the underlying media was not affected by losartan within 10 days after injury ( Figure 1B ). Losartan significantly reduced (bỹ 50%) total aortic DNA content at Day 10 although not at Day 5 (Table 1) . Consistent with these results, losartan significantly reduced by 56% the number of neointimal SMC nuclei at Day 10 but not Day 5, as compared with the time-matched placebo (Figure 2A) . In contrast, the number of medial SMC nuclei in the losartan group showed a significant increase at Day 5 but not at Day 10 ( Figure 2B ). In addition, the total aortic DNA content (Table 1) correlates with the total number of SMC nuclei ( Figure 2 ) (neointima plus media) at Days 5 and 10 after injury, in both the placebo and losartan groups.
DNA analysis
Cell death by apoptosis is characterized by specific 
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internucleosomal DNA fragmentation, a feature that appears as a DNA ladder after agarose gel electrophoresis ( Figure 3A) . The DNA fragmentation index (see Methods) for the whole aorta of the placebo groups were similar between Days 5 and 10 ( Figure 3B ). In comparison with placebo, losartan-treated rats showed marked 2.6-fold and 4.1-fold increases in the DNA fragmentation index at Days 5 and 10 after injury respectively, compared with their time-matched placebo ( Figure 3B ). The distribution of apoptotic SMC within the injured arterial wall was analyzed by in situ TdTlabeling.
In order to control for specificity of the TdT-labeling assay, we used specimens of small intestine and confirmed that TdT-positive cells were detected in the intestinal epithelium, almost exclusively at the tip of the villi.As previously reported by others, 19, 20 the neointima showed markedly higher basal values of TdT-positive SMC than the underlying media (Figure 4) , with a predominant localization at the luminal surface of the lesion. Placebo values in the neointima appeared stable between Days 5 and 10 after injury. Consistent with the DNA fragmentation data described above, losartan treatment induced significant 61% and 68% increases in TdTlabeled neointimal SMC at Days 5 and 10 respectively, as compared to the time-matched placebo ( Figure 4A ).
Although placebo values for TdT-labeling in the media were different between Days 5 and 10, a feature previously reported for this period after injury, 20 it was evident that losartan enhanced apoptosis in the media at Day 10 but not Day 5 ( Figure 4B ). Collectively, these results suggest that, compared with placebo treatment, losartan induced a steady increase in cell death by apoptosis between Days 5 and 10 after injury, predominantly in the neointima. Losartan reduced in vivo 3 H-thymidine incorporation at Day 5 but not Day 10 after balloon angioplasty as compared with placebo, suggesting transient inhibition of DNA synthesis by losartan at Day 5 after injury ( Table  1) .
Identification of endothelial cells
The regrowth of endothelial cells overlying the neointima was monitored by in situ detection of von Willebrand factor. These studies revealed the presence of regenerated endothelial cells at the surface of the neointima at Days 5 and 10 (data not shown).
Consequently, the first cell layer of the neointima was not included in the quantitative assessment of cell number and in situ TdT-labeling.
Discussion
Previous studies in rats showed that AT 1 -receptor antagonists inhibit neointima formation in part by suppressing the stimulation of SMC proliferation in the media during the first week after injury. 21 In contrast, the sustained neointimal SMC proliferation that occurs beyond 4 days after injury is not suppressed by AT 1 antagonists.
In the present study, we report that losartan decreased total aortic DNA synthesis at Day 5 after injury, i.e. at a time when SMC proliferation is still significant in the media, but not at Day 10, when proliferation is predominantly neointimal. 22 In the uninjured SHR aorta where only medial SMC are present, however, we previously reported that the steady state levels of aortic DNA synthesis are reduced in a sustained manner by losartan. 15 Thus, the transient inhibition of DNA synthesis by losartan probably reflects the fact that medial proliferation predominates over neointimal proliferation only transiently after injury, and that it is medial proliferation which may be inhibited by losartan. Apoptosis is emerging as a key determinant of cardiovascular remodeling. Transient induction of apoptosis, the mechanisms of which remain poorly defined, have been observed in models of cardiovascular mass regression as well as hypertrophy development. 15, 18, [23] [24] [25] Notably, numerous studies have reported an increase in SMC apoptosis after balloon injury which reached peak values within 9 to 20 days. 19, 20, [25] [26] [27] [28] The regulation of SMC apoptosis in the injured artery remains poorly defined. Genes involved in the apoptotic process such as bcl-x s and caspase-1 are increased in vascular lesions. 26 Apoptosis is also observed in human atherosclerotic plaques in different cell types, predominantly macrophages and SMC. 20, [29] [30] [31] [32] A lower incidence of apoptosis has been described in restenotic human arteries. 28 In the present study, we confirm the previous reports that SMC apoptotic activity after injury is significant and localized predominantly in the luminal layers of the lesion. Moreover, the levels of apoptosis observed in the underlying injured media are consistent with the observations of Han et al. 20 Taken together, these data suggest that enhanced SMC proliferation after injury is in part counterbalanced by increased cell death by apoptosis. The significant new finding of this study is that losartan treatment significantly enhanced SMC apoptosis by more than 2-fold and 4-fold at Days 5 and 10 after injury respectively, compared with the time-matched placebo group.Although cell types have not been formally identified in the injured arterial wall, the following arguments suggest that SMC were the main cell type undergoing apoptosis in the present study. Previous studies showed that leukocytes are rare in the rat neointima. 17, 33 Furthermore, immuno-staining for an endothelium-specific marker (von Willebrand factor) allowed us to confirm the presence of endothelial cells at the luminal surface of the lesion. Luminal neointimal cells were thus excluded from the total cell number quantification and in situ TdT-labeling analyses. Finally, SMC are by far the predominant cell type in the rat neointima. 21 Evidence for apoptosis include a significant increase in internucleosomal DNA fragmentation in the injured artery of the losartan-treated group as compared with placebo. In addition, in situ TdT-labeling demonstrated that losartan-induced apoptosis was more pronounced in the neointima than in the underlying media. For instance, losartan enhanced apoptosis at Days 5 and 10 in the neointima but only at Day 10 in the media. In a previous study, we observed that a 2-week treatment with losartan induces apoptosis in more than 30% of the SMC in the uninjured media of SHR. 15 In the present study, the effect of losartan on total cell number appeared marginal in the injured media, whereas it was significant in the neointima. Thus, vascular injury may attenuate the apoptotic response to AT 1 -receptor blockers in the aortic media. Nevertheless, losartan-induced apoptosis may have contributed to reduce the number of SMC in the media between Days 5 and 10. Inhibition of SMC migration by losartan 7,21 may explain the transient increase in medial SMC number at Day 5 in the losartan-treated group compared with the time-matched placebo group. It is intriguing to speculate that the SMC that did not migrate out of the media due to AT 1 -receptor blockade with losartan were not viable and subsequently underwent cell death by apoptosis.The observation that losartan-induced SMC apoptosis is regulated differently in adjacent smooth muscle layers, i.e. neointima and media, is reminiscent of our previous observation that neointimal SMC exhibit an enhanced proliferative response to angiotensin II in vivo, compared with SMC in the underlying media. 17 In summary, the present data suggest that both inhibition of SMC DNA synthesis and of SMC apoptosis by losartan may contribute to suppress vascular lesion development, although with different time courses after injury. Several mechanisms may contribute to the induction of SMC apoptosis by losartan. First, AT 1 -receptor blockade may deprive SMC of a key survival signal. Consistent with this,AT 1 -receptor stimulation inhibits SMC apoptosis in vitro. 34 Secondly, we have recently demonstrated that losartan-induced SMC apoptosis is dependent on elevated plasma angiotensin II levels and activation of AT 2 -receptors which are expressed in the uninjured SHR aorta. 35 It was recently demonstrated that AT 2receptors are upregulated after balloon injury in the rat carotid artery. 36 Although we did not investigate the presence of AT 2 -receptors in the present study, it is intriguing to speculate that overstimulation of proapoptotic AT 2 -receptors in the neointima may have contributed to SMC apoptosis in this model. Finally, the possible role of blood pressure changes with losartan needs to be discussed.We previously reported that the present dose of losartan reduces blood pressure and induces medial SMC apoptosis in the uninjured aorta of SHR. 15 In contrast, in the same model an equipotent antihypertensive dose of hydralazine does not affect medial SMC apoptosis. 15 In the present study, it is noteworthy that the apoptotic response to losartan was markedly different in adjacent smooth muscle layers, i.e., the media and neointima, particularly at Day 5. Together, these observations reinforce the notion that losartan induction of SMC apoptosis involved a strong pressure-independent component. However, we cannot rule out the possible contribution of mechanical factors since unloading of wall tension was recently shown to induce SMC apoptosis in vivo in rabbit carotid arteries. 37 Apoptosis is emerging as a novel therapeutic approach to control intimal thickening in atherosclerosis and vascular injury. Administration of antisense oligonucleotides to suppress intimal expression of the apoptosis suppressor gene bcl-x L results in the regression of vascular lesion in rabbits. 38 Dietary supplementation with L-arginine induces macrophage apoptosis and regression of pre-existing atherosclerotic lesion in hypercholesterolemic rabbits. 39 The present study suggests that AT 1 antagonists, a widely used class of antihypertensive agents, may be effective in the prevention of vascular occlusive diseases in part via the induction of SMC apoptosis. Overall, the present study provides further evidence supporting the hypothesis that angiotensin II is an important regulator of SMC growth and survival in vascular disorders.
